
Mast Cell Activation Syndrome




Brayden Yellman, MD

University of Utah Health Project ECHO

July 26, 2022

Brief Mast Cell Review

- Mast cells are a type of **white blood cell** found in connective tissues of the body, under the skin, near blood vessels and lymph vessels, in nerves, and in the lungs and intestines.
- Mast cells are prominent **near the boundaries between the outside world and the internal milieu**, such as the skin, mucosa of the lungs, and digestive tract, as well as the mouth, conjunctiva, and nose.



- Although best known for allergy and anaphylaxis, mast cells are involved in wound healing, angiogenesis, immune tolerance, defense against pathogens, and vascular permeability.

Disordered mast cell activation occurs when mast cells are pathologically **overproduced** or if their **activation is out of proportion** to the perceived threat to homeostasis.

Mastocytosis: rare and includes a variety of conditions with TOO MANY mast cells.

- Cutaneous mastocytosis
- Systemic mastocytosis
- Mast cell leukemia
- Mast cell sarcoma
- Others...

MCAS: Mast Cell Activation Syndrome refers to a group of disorders with diverse causes presenting with **episodic** multisystem symptoms as the result of [excess] mast cell mediator release.

Anaphylaxis is an extreme example of inappropriate mast cell activation.

Mast Cell Activation

- When mast cells are “activated,” inflammatory chemicals or “mediators” are released from granules. **Histamine, leukotrienes, prostaglandins** are familiar examples. **Tryptase** is the most specific for MC (but may be more difficult to detect).
- Locally activated mast cells may also send distress signals, through the nervous system and immune system, often propagating a neuroinflammatory response to other distal areas of the body.





Table 1.









Common Mast Cell Mediators and their Associated Symptoms.

Mast Cell Mediator	Associated Symptoms
Tryptase	Easy bruising and bleeding, fatigue, myalgias, vertigo, flushing, diarrhea, edema
Histamine	urticaria, pruritis, anaphylaxis, diarrhea, angioedema, headache, hypotension
Proteoglycans	Bleeding
Prostaglandin D2	headache, brain fog, abdominal pain, nausea, bronchoconstriction
Platelet activation factor	cardiac arrhythmia, bronchoconstriction, urticaria, abdominal pain
Interleukins	inflammation
Tumor necrosis factor alpha	fatigue
Leukotrienes	bronchoconstriction, mucous production



Mast Cell Activation/Hypersensitivity Triggers

Figure 1. Some *Potential* Mast Cell Triggers²⁻⁵

- Heat, cold or sudden temperature changes 
- Stress: emotional, physical, including *pain*, or environmental (i.e., weather changes, pollution, pollen, pet dander, etc.) 
- Exercise 
- Fatigue
- Food or beverages, including alcohol 
Food, Glorious Food
- Drugs (opioids, NSAIDs, antibiotics and some local anesthetics) and contrast dyes 
- Natural odors, chemical odors, perfumes and scents 
- Venoms (bee, wasp, mixed vespids, spiders, fire ants, jelly fish, snakes, biting insects, such as flies, mosquitos and fleas, etc.) 
- Infections (viral, bacterial or fungal) 
- Mechanical irritation, friction, vibration
- Sun/sunlight 



Common Symptoms of MCAS

- **Anaphylaxis**



- **Dermatological**




- **Cardiovascular**



- **Gastrointestinal**



- **Respiratory**



MAST CELL MEDIATOR SYMPTOMS

Anaphylaxis

Flushing of the face, neck, and chest

Itching, +/- rash

Hives, skin rashes

Angioedema (swelling)

Nasal itching and congestion

Wheezing and shortness of breath

Throat itching and swelling

Headache and/or brain fog, cognitive dysfunction, anxiety, depression

Diarrhea, nausea, vomiting, abdominal pain, bloating, gastroesophageal reflux disease (GERD)

Bone/muscle pain, osteosclerosis, osteopenia, osteoporosis

Light-headedness, syncope/fainting

Rapid heart rate, chest pain






Low blood pressure, high blood pressure at the start of a reaction, blood pressure instability

Uterine cramps or bleeding



Clinical criteria for mast cell activation syndrome

1) Episodic symptoms consistent with mast cell mediator release affecting **two or more organ systems** evidenced as follows:

- Skin: urticaria (hives), angioedema (sudden swelling), flushing,  dermatographia
- Gastrointestinal: nausea, vomiting, diarrhea, abdominal cramping 
- Cardiovascular: hypotensive syncope (fainting), tachycardia 
- Respiratory: wheezing 
- Naso-ocular: conjunctival injection, pruritus(itching), nasal stuffiness 

Clinical criteria for mast cell activation syndrome


2) Improved symptoms after treatment with:

- H1 (antihistamines) and H2 (famotidine) histamine receptor antagonists
- Leukotriene antagonists: montelukast
- Mast cell stabilizers – cromolyn sodium, ketotifen (also an antihistamine)

CLINICAL CRITERIA FOR MAST CELL ACTIVATION SYNDROME

3) Elevation of a validated urinary or serum marker of mast cell activation:

- Total serum **tryptase** (very specific for mast cells)
- Plasma **prostaglandin D2, histamine**
- Biopsy tissue (i.e. GI tissue) with staining positive for increased numbers of mast cells (CD 117 staining)
- 24-hour urine levels of:
 - **N-methylhistamine**
 - **11B -Prostaglandin F2 α** (11B-PGF2 α)
 - **Leukotriene E4 (LTE4)**



REMEMBER: Empiric trials of therapy when there is a clinical suspicion for MCAS can also be diagnostic!

Relevance of MCAS to Our Topic?

The acute COVID-19 “cytokine storm” is characterized by rapid proliferation and hyperactivation of T cells, macrophages, and natural killer cells, and the overproduction of >150 inflammatory cytokines and chemical mediators released by immune or nonimmune cells. Mast cells (MCs) are activated by SARS-CoV-2.

- **Dual-histamine receptor blockage with cetirizine-famotidine reduces pulmonary symptoms in COVID-19 patients.** R.B. Hogan 2nd, R.B. Hogan 3rd, T. Cannon, et al. Pulm Pharmacol Ther. Epub 2020 Aug 29. PMID: 32871242 <https://pubmed.ncbi.nlm.nih.gov/32871242/>
- **Histamine receptors and COVID-19.** M. Ennis, K. Tiligada. Inflamm Res. 2021 Jan. Epub 2020 Nov 18. PMID: 33206207. <https://pubmed.ncbi.nlm.nih.gov/33206207/>
- **Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome.** Afrin LB, Weinstock LB, Molderings GJ. Int J Infect Dis. 2020 Nov; Epub 2020 Sep 10. PMID: 32920235 <https://pubmed.ncbi.nlm.nih.gov/32920235/>

Relevance of MCAS to Long COVID or ME/CFS

- **Questionnaires** were given to
 - 136 Long COVID
 - 136 Healthy Controls
 - 80 MCAS patients (5 systems)
- **Mast cell activation symptoms are prevalent in Long-COVID.** Leonard B Weinstock, Jill B Brook, Arthur S Walters, Ashleigh Goris, Lawrence B Afrin, Gerhard J Molderings. Int J Infect Dis. 2021 Nov. Epub 2021 Sep 23. PMID: 34563706.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459548/>

Mean Mast Cell Mediator Release Syndrome scores for each group with whiskers showing 95% confidence intervals






Figure 3

Spider web plots
of mean mast cell
mediator release
syndrome scores.


General Population Controls




MCAS Patients Prior to Therapy




Pre-COVID-19 Long-COVID Participants




Post-COVID-19 Long-COVID Participants



Mast cell-associated disease-specific pain syndromes, mast cell activation and its common activators:



Mast Cell Disease Coexisting Conditions



MastCellDisease.com

- Abnormal laboratory testing refers to those with POTS whose laboratory workup suggested elevated MCAS-related serum and urine mediators

Table 3

Comparison of Symptoms in 44 Patients Who Underwent Laboratory Testing

	Abnormal Laboratory Tests (n=29) %		Normal Laboratory Tests (n=15) %		P Value
Age, y, mean±SD	34±9.5		33 ± 12.2		NS
% Female	29/29		13/15		0.111
Palpitation	25/29	86	13/15	87	1.0
Syncope	11/29	38	4/15	27	0.524
Fatigue	21/29	72	8/15	53	0.317
Lightheadedness	23/29	79	11/15	73	0.714
/dizzy/brain fog					
Migraines	11/29	38	3/15	20	0.314
Depression/anxiety	6/29	21	6/15	40	0.284
Fibromyalgia	4/29	14	1/15	7	0.647
Allergy	13/29	45	2/15	13	0.048
Skin rash	10/29	34	1/15	13	0.067
Gastrointestinal symptoms	18/29	62	3/15	23	0.001


POTS with "Atypical Symptoms"

NS indicates not significant.


Table 2


Comparison of Symptoms in 44 Patients Who Underwent Laboratory Testing

Abnormal Values	POTS-like With Atypical Symptoms	POTS Alone	P Value
	(n=29)	(n=15)	
ESR or CRP abnormal	6/28* (21%)	3/14* (21%)	>.99
Tryptase	2/23* (9%)	0/9* (0%)	>.99
Prostaglandin	16/28* (57%)	0/15 (0%)	0.0002
Histamine	17/29 (59%)	0/15 (0%)	0.0001
Histamine or methylhistamine abnormal	23/29 (79%)	0/15 (0%)	0.0001



- Nociceptive inputs from these primary afferent fibers signaling peripheral inflammation or other noxious stimuli are relayed through the dorsal root ganglion (DRG) into the spinal dorsal horns
- These signals are then transmitted to second-order neurons in the trigeminal nucleus caudalis (TNC) within the brainstem






- 1 Binding of CGRP receptor antagonists (red) to receptors located on mast cells inhibits inflammation caused by trigeminal release of CGRP (blue) onto mast cells within the outer covering of the brain (meninges)



From N Engl J Med, Durham PL, CGRP-Receptor Antagonists — A Fresh Approach to Migraine Therapy? 350:1073-1075, Copyright © 2018 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

- The trigeminal nuclear complex (including the trigeminal nucleus caudalis (TNC) and its related extensions at C1-C2) then send afferent signals to second order neurons
- This signaling is often through trigeminal neuron release of **substance P** and **CGRP** acting upon meningeal vessels of the trigeminovascular system and upon **dural mast cells**
- This activation can lead to triggering or propagation of **migraine** and of **central pain sensitization**



Mast Cell Activation Treatments

- Low Histamine Diet
- Diamine oxidase (reduce histamine levels in foods)
- H1 Blockade (fexofenadine, loratadine, cetirizine, levocetirizine)
- H2 Blockade (famotidine, ranitidine, cimetidine)
- Benadryl (diphenhydramine)
- Leukotriene Blockade (montelukast)
- Mast Cell Stabilizers
 - Liquid cromolyn/Gastrocrom (1 mL or 20 mg up to 5 ml or 100 mg 15 minutes before meals and medications)
 - Compounded cromolyn sodium (200 mg po tid to qid)
 - Compounded ketotifen (1 mg po bid)
 - OTC Quercetin
- Anti-IgE biologics (omalizumab/Xolair)



REMEMBER: Empiric trials of therapy when a clinical suspicion for MCAS can also be diagnostic!